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Abstract.  We have investigated the binding of soluble 
tenascin-C  (TN-C) to several cell lines using a radio- 
ligand binding assay.  Specific binding was demon- 
strated to U-251MG human glioma cells and to a line 
of bovine aortic endothelial cells, but hamster fibro- 
blasts showed no specific binding.  Recombinant pro- 
teins corresponding to specific domains of TN-C were 
used to map the binding site(s) in TN-C.  The alterna- 
tively spliced segment (TNfnA-D) inhibited the bind- 
ing of native TN-C most strongly,  and itself bound to 
glioma and endothelial cells. Scatchard analysis of 
TNfnA-D binding indicated 2-5  x  105 binding sites 
per cell, with an apparent 2 nM dissociation constant. 
The cell surface receptor for TNfnA-D was identified 
as a 35-kD protein on the basis of blot binding assays 
and affinity chromatography of membrane extracts on 
native TN-C and TNfnA-D columns. Protein sequenc- 
ing indicated that this 35-kD receptor was annexin lI. 
Annexin 11 is well characterized as a cytoplasmic pro- 
rein,  so it was surprising to find it as a presumably 
extraceLlular  receptor for TN-C.  To confirm that it was 
the 35-kD receptor,  we obtained purified annexin lI 
and demonstrated its binding to TNfnA-D and TN-C 
at nM concentrations.  Antibodies to annexin II promi- 
nently stained the external surface of live endothelial 
ceils and blocked the binding of TNfnA-D to the cells. 
Thus annexin II appears to be a receptor for the alter- 
natively spliced segment of TN-C, and may mediate 
cellular responses to soluble TN-C in the extraceLlular 
matrix. 
T 
ENASCIN-C (TN-C) 1 is the first discovered  member 
of the tenascin  family, which now includes  TN-R and 
TN-X (9, 25, 29, 52). TN-C was described as a hexa- 
brachion because it exists as a hexamer of 220-320 kD elon- 
gated subunits  (26). Each subunit of TN-C comprises three 
types of structural modules: EGF-like domains,  FN-HI do- 
mains,  and a terminal  knob homologous to the beta- and 
gamma-chains  of fibrinogen,  as shown in Fig.  1. The multi- 
domain structure of the TN-C suggests the possibility of mul- 
tiple-independent  functions  (27). 
TN-C shows a restricted expression pattern during the de- 
velopment. It is selectively present in the mesenchyme sur- 
rounding growing epithelia in organs (3). TN-C is prominent 
in specific layers of developing  brain (6,  19) and it is dis- 
tributed along the principal  neural crest cell migration  path- 
ways (10, 19, 55, 56). TN-C is prominent in differentiating 
bone and cartilage (13, 48). Although TN-C is missing from 
most adult tissues, it reappears at places where active tissue 
regeneration  and cell migration  occurs, namely in a large 
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range of tumors (14, 41), in wound healing (17, 44, 47, 60), 
and in regenerating  nerves (20, 30). A very important recent 
study reported that mice genetically engineered to eliminate 
TN-C developed normally (57). This has led to much discus- 
sion, including  suggestions  that TN-C (and any other pro- 
tein) may be expressed in some tissues where it has no func- 
tion (24), and that its functions axe subtle rather than vital. 
It is clear, however, that TN-C and probably the whole tenas- 
cin family are conserved in every vertebrate species, so these 
molecules must have  functions  that  contribute to survival 
(25). Experiments  in cell culture will continue to provide im- 
portant clues about possible functions in the living animal. 
The possibility of cell surface receptors for TN-C has been 
investigated so far mainly by cell adhesion assays. Cells bind 
to  TNfn3  (which  has  an  RGD  sequence  in  human  and 
chicken TN-C, but not in other species) via the o~v/33 inte- 
grin, and to TNfbg via a proteoglycan or the a2/~l integrin 
(4,  36, 54, 58). A positive result in a cell adhesion  assay 
clearly demonstrates a cell surface receptor, but some recep- 
tors may not give cell adhesion.  To look for additional  cell 
surface receptors for TN-C, we have now assayed directly 
the binding  of soluble TN-C to cells. 
There is growing evidence that TN-C may affect cells as 
a soluble ligand.  Native TN-C and a recombinant domain 
TNfnA-D (see Fig.  1 and caption for nomenclature of do- 
mains and recombinant proteins), acting as soluble ligands, 
are able to provoke the loss of focal adhesions in well spread 
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The Journal of Cell Biology, Volume 126, Number 2, July 1994 539-548  539 endothelial  cells  (5  I),  and inhibit  adhesion of  uterine  epithe- 
lial  cells  to  matrigel  (37).  End ct  al.  (22)  reported  that  TN-C 
has mitogenic activity,  distinct  from the signaling  pathways 
induced by peptide growth factors.  Although the mitogenic 
activity  needs to  be further  examined (e.g.,  Crossin reported 
an inhibition  of  mitogenesis by TN-C [18]),  we believe  that 
TN-C  may affect  cellular  regulation  through cell surface 
receptors.  It  is  therefore  important to  determine whether do- 
mains of  TN-C, as soluble  ligands,  bind to receptors  on the 
cell surface. 
In the present study, we have done binding  assays using 
soluble  radiolabeled  ligands.  We  first  demonstrated  the 
specific  binding  of native  TN-C  to  endothelial  cells and 
glioma cells.  Then,  using recombinant segments  of TN-C 
(4), we mapped the major binding site to TNfiaA-D, the alter- 
natively  spliced  segment.  A  single  class  of high  affinity 
receptor on endothelial  cells has been defined by Seatchard 
analysis, and biochemical characterization  and identification 
of the receptor are presented. 
Materials and Methods 
Cells and Cell Cultures 
A human glioma cell line U-251MG  (clone 3, obtained from Dr.  Darell 
Bigner, Duke University), the bovine endothelial cell line GM7373 (from 
Coriell Institute for Medical Research, Camden, NJ, (33)), and the hamster 
fibroblast cell line NIL.gM (from Dr. Richard Hynes, MIT) were grown in 
DMEM, high glucose supplemented with 10% heat inactivated FCS. 
Proteins and Antibodies 
TN-C was purified from culture supernatant of U-251MG human glioma 
cells by gel filtration and mono Q ion exchange  chromatography as de- 
scribed by Aukhil et al.  (5).  Fibronectin (FN) was purified from human 
plasma or horse serum by gelatin-agarose  affinity chromatography (23). 
Mouse laminin from EHS tumors was a generous gift from Dr.  Hynda 
Kleinman, NIH. Bacterial expression proteins were purified  as described 
by Aukhll et al. (4). TN-C, and TN-C segments TNfnA-D and TNfn3 were 
iodinated by the Chioramine T method (32) to a specific activity of 3-10 
mCi/mg. The integrity of the labeled ligend was ascertained by SDS-PAGE 
followed by autoradiography.  Anti-annexin  II antiserum and purified bovine 
aunexin H was provided by Dr.  Carl Creutz, University of Virginia.  An- 
nexin II was also purified in our lab from bovine lung as described by Drust 
and Creutz (21). Affinity-purified anti-annexin II antibody was prepared on 
a  column of 0.6 nag annexin II coupled to cyanogen  bromide-activated 
Sepbarose.  Bound antibody was eluted with 0.1 M glycine, pH 2.6, and neu- 
tralized.  Affinity-purified anti-spectrin antibody was provided by Dr. Vann 
Bennett, Duke University. 
Binding Assay 
The  binding  assay  was  done  in  DMEM/Hepes  (N-2-hydroxyethyl- 
piperazine-N'-2-ethane sulfonlc acid, pH 7.4) supplemented with 0.2 % bo- 
vine serum albumin (BSA) (bInding medium). Cells were seeded on 24 well 
cell culture plates (Nunc,  Naperville, IL) at a density of 2  x  105 cells per 
well. After 24 h, cultures were rinsed two times with PBS (pH 7.4, 137 mM 
NaC1, 2.7 mM KC1, 1.5 mM KH2PO4, 8 mM Na2HPO4) and preincubated 
in a CO2 incubator with binding medium for 10 min at 37°C, and then in- 
cubated' with binding medium containing the iodinated ligend for 1 h at 
37"C.  Preliminary experiments showed that 125I-TN-C bound to glioma 
cells in a time dependent manner and reached equilibrium in ,v30 rnin at 
37°C (not shown).  Subsequent assays were done at a 60-rain binding time. 
After incubation, cells were rinsed three times with ice-cold DMEM/Hepes 
and cell layers were extracted in 4% SDS. The radioactivity of the extracts 
was counted in a gamma counter. 
For binding assay to cells in suspension, cells were incubated with PBS 
containing 3 mM EDTA and 1 mM PMSF for 5 rain at 37°C and harvested 
by gentle pipetting.  Cells were centrifuged and re,  suspended in DMEM/ 
Hepes,  and then recentrifugad.  The pellet was  resuspended in DMEM/ 
Hepes containing 0.2%  BSA, and the cell concentration was determined 
with a hemocytometer.  Cell viability was between 85-95%, determined by 
the trypan blue exclusion method. Assays were done in 300 #1 suspeusious 
of cells (1-3  x  105 cells per tube) with iodinated ligend and with or with- 
out unlabeled llgend.  After 1 h incubation at 37"C with regular shaking, 
cells were layered onto two-step  sucrose gradients in Titermbes (Bio-Rad 
Labs., Hercules, CA) (bottom: 0.3 mi of  0.7 M sucrose; top: 0.5 mi of  0.3 M 
sucrose in binding medium). The tubes were spun for 15 rain at 2,500 
rpm in a CPR 3000 centrifuge (swinging bucket rotor) (Beckman Instrs., 
Inc., Fuilerton, CA). Tubes were frozen in dry ice, the bottoms were cut 
off, and the radioactivity was counted. 
AJJinity Chromatography 
To identify and isolate the receptor, native TN-C, TNfnA-D,  TNf-n3, FN, 
and  BSA  were  immobilized  separately  on  cyanogen  bromide-activated 
Sepharose 413 beads (Sigma Chem. Co., St. Louis, MO). To detect surface 
proteins only, cell surface proteius were radioiodinated using lactoperoxi- 
dase.  Approximately,  108 cells suspended in 2 ml PBS were iodinated in 
the presence of 1 mCi 125I-sodium iodide,  0.1 mg/ml of lactoperoxidase 
and  15  ~1 of 0.3%  H202.  After  10 rain incubation on ice,  cells were 
washed three times with column buffer  (20 mM Tris,  pH 7.4,  150 mM 
NaCI,  1 mM CaC12, 1 mM MnCI2,  1 mM MgC12) and lysed in 2 ml of 
column buffer containing 100 mM octylglucoside  and 1 mM PMSF by vor- 
texing and incubating on ice for 20 min. The extracts were centrifuged at 
12,000 g for 10 min to remove insoluble cytoskeletal  and nuclear compo- 
nents.  To test if the receptor for TN-C can be solubflized with detergent, 
proteins in the detergent extract was incorporated into pbosphatidylchollne 
liposomes as described by Mimms et al. (50) and binding assay was done 
with liposomes.  125I-TNfnA-D specifically bound to llposomes,  which in- 
dicates that the receptor is detergent-soluble (not shown). 
The detergent extract of labeled cells was subjected to affinity chroma- 
tography. Cell extract was first preincubated with Sepharose 413 to remove 
nonspecific binding, and then applied to the altinlty matrix that had been 
equilibrated with column buffer containing 30 mM octylglucoside,  1 mM 
PMSF, 1 mM NEM (n-ethylmaieimide)  (starting buffer). Protein not bound 
to the column was recovered upon washing the column with 4 mi of starting 
buffer, Bound components were eluted by washing the column sequentially 
with 0.3  M NaCI,  1 mg/ml GRGDSP peptide,  and 4  M urea in starting 
buffer. Eluted fractions were subjected to SDS-PAGE analysis and visual- 
ized by autoradiography. 
The 35-kD receptor for tenascin was purified from bovine lung in a 
scaled up protocol. Bovine lung (150 g) was homogenized  in a blender in 
500 mi of 20 mM Hepes, 200 mM sucrose, 2.5 mM EDTA,  1 mM PMSF, 
and 0.02 % sodium azide.  The homogenate was further homogenized with 
a polytron and centrifuged at 16,000 g for 45 min. The supernatant was then 
centrifuged at 110,000 g for 2 h and the pellet (membrane fraction) was solu- 
bilized with 0.2% Triton X-100 in D-TBS (20 mM "IYis, pH 7.4,  150 mM 
NaCI,  1 mM CaCI2, 1 mM MgC12). After centrifuging at 10~00 g to re- 
move cytoskeletal  proteins, the detergent-soluble extract was loaded onto 
TN-C or TNfnA-D affinity columns (10 ml column). A 35-kD tenascin- 
binding protein  (TBP-35),  identified  by  Coomassie-blue stained  SDS- 
PAGE, was eluted from both TN-C and TNfnA-D affinity columns with 
0.5 M NaC1 or 4 M urea. 
To raise antibodies against TBP-35, the peak from the affinity column was 
run on 10% SDS-PAGE and the TBP-35 band was cut, minced, and mixed 
with a complete Freud's adjuvant. A rabbit was immunized by subcutaneous 
injectious of this mixture,  followed by two boosts.  The titer and specificity 
of antiserum were tested with immunoblotting and ELISA. 
Amino Acid Sequencing 
Partially purified TBP-35  from the bovine lung preparation was concen- 
trated with a Centricon (Amicon, Inc., Beverly, MA) and further purified 
by gel filtration using a Superose-12 column (1  ×  30 cm) in the presence 
of 0.2%  of Triton X-100 in D-TBS. TBP-35 was present in late fractious. 
Fractions containing TBP-35 were pooled, concentrated, and run on 10% 
SDS-PAGE. The resolved proteins were transferred to a nitrocellulose sheet 
(Schieicher and Schuell, Keene, NH) and the blotted membrane was rinsed 
with Mdi-Q water,  stained with 0.1% Poncean S in 1% acetic acid, and 
briefly rinsed with Mfli-Q water. The band was carefully cut out with a scal- 
pel and sent to Dr. W'dliam S. Lane, Harvard Microcbemistry Facility (Bos- 
ton, MA). Tryptic  digestion,  HPLC,  and NH2-terminal  sequencing were 
done as described by Aebersold et al. (1). TBP-35 usually appeared as a dou- 
blet band on SDS gels.  The smaller protein band was sequenced. 
The Journal of Cell Biology, Volume 126, 1994  540 Domain  structure  of  the  tenascin  arm 
Central  noduh  Terminal  knol~ 
EGF domains  FN-III domains  (flbrlnogen) 
~  universal, 
....................................................................................... 
Tenascin:  bacterial 
expression  proteins  TNfnl.5 ~  TNfn6-8~ 
TNfn3 ~  TNfnA-D  TNfbg 
Figure  I.  A  schematic  dia- 
gram of the multidomain struc- 
ture of human TN-C, and the 
repertoire of bacterial expres- 
sion proteins we  have  used. 
The abbreviations used in the 
text are indicated on the figure. 
Flow Cytometric Analysis and 
Immunofluorescence Staining 
Endothelial cells were harvested with 3 mM EDTA in PBS, suspended  in 
D-TBS and cooled to 4"C. 106 cells were put in each assay tube. Primary 
antisera was added with a final dilution of 1:100 for preimmune,  annexin 
II, and TBP-35 antiserum.  The afffinity-purified  spectrin  antibody  was added 
to a final concentration  of 5 ~g/ml. Cells were incubated  with the primary 
antibodies for 1 h at 4"C, washed three times with ice-cold D-TBS, and 
resuspended  with fluorescein-eunjugated  goat anti-rabbit  IgG at a final  dilu- 
tion of 1:100 for 30 re.in  at 4°C. Cells were then washed three times, fixed 
with 3 % freshly  made  paraformaldehyde  (necessary  to prevent  cell aggrega- 
tion), and resuspended  in I ml D-TBS  at 4"C. Flow  cytometric  analysis  was 
done with a Beetun-Dickinson  model FACSean  flow cytometer. 
For immunofluorescenee  staining,  endothelial  cells were grown in Lab- 
tek chamber slides (Nunc), washed with PBS, and fixed for 5 rain with 
freshly made 3 % para-formaldehyde  in PBS. After washing  cells with PBS, 
remaining  formaldehyde  was neutralized  with 50 mM NI-I4CI. Cells were 
either directly  stained  or permeabilized  with 0.2 % Triton  X-100 in PBS for 
5 rain before staining, Primary antisera were added at a final dilution of 
1:100 in PBS, and incubated  for 1 h at 4°C. Cells were washed three times 
with PBS for 15 rnin and fluorescein  or rhodamine-conjugatad  goat anti- 
rabbit 18(3 (Tago, Inc., Burlingame,  CA) was added at a final  dilution 1:100. 
The chambers  were detached carefully  and slides  were mounted  for obser- 
vation and photography. 
Results 
Cell Binding of  Labeled TN-C 
Three types of cells were tested for the binding of TN-C. 
U-251MG human glioma cells, which secrete high levels of 
human TN-C, have shown weak cell adhesion to TN-C sub- 
strates  (8,  46).  A  line of transformed bovine aortic  en- 
dothelial cells, GM7373, was chosen to be tested because 
soluble TN-C has been shown to induce the loss of focal 
adhesion in endothelial cells (51) and because these cells ad- 
here to TN-C substrates (36).  The hamster fibroblast line 
NIL.SM was chosen as a  third, unrelated cell type which 
does not adhere to TN-C substrates (46). 
The binding of t2SI-TN-C to U-251MG and GM7373 cells 
was significantly inhibited by increasing amounts of unla- 
beled TN-C,  demonstrating the  specificity of the binding 
(Fig. 2 A). About 50% ofthe total binding  was specific, mean- 
ing it could be competed by an excess of unlabeled TN-C, 
in both glioma and endothelial ceils. The high non-specific 
binding ('~,50%  of total binding) is commonly observed in 
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Figure 2. Competition by un- 
labeled TN-C  for  1~I-TN-C 
binding to  cells  attached  to 
the substrate  (A) and to cells 
in suspension (B).  (.4) Cells 
were plated on 24-well tissue 
culture plates  at a density of 
1-2  ×  10  ~ cells per well, and 
tested  24 h  later.  Unlabeled 
TN-C was  added  in varying 
amounts together  with  100- 
200 ng/ml of labeled ligands 
(0.5-1  x  106 cpm per ttg) to 
cells.  The  concentration  of 
unlabeled  TN-C for half max- 
imal  competition  was  ~0.7 
nM. (B) Suspended ceils were 
obtained  by the treatment with 
3 mM EDTA.  100-200 ng of 
~I-TN-C (0.5-2  x  106 epm per #g) was added to suspended cells (5  ×  105 cells per assay sample) with or without unlabeled TN-C. 
Each data point is the mean of two measurements. The experiments  were repeated  three times, showing very similar inhibition. 100% 
represents  the binding in the absence of unlabeled TN-C. 
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fibronectin and laminin. Specific binding was much lower to 
NIL cells, indicating either a lack of  high affinity  binding sites 
or a small number of sites.  To assure the integrity of bound 
TN-C, we compared the t~-TN-C before and after binding 
to  cells by means of SDS-PAGE.  There was  no mobility 
change of TN-C after incubation with cells, indicating no ma- 
jor degradation or modification by cells (not shown). 
We tested several possible mechanisms for the non-specific 
binding.  Since TN-C has been reported to bind to several 
ECM molecules and proteoglycans (4, 15, 28, 34, 43, 49), we 
tested the binding of TN-C to the ECM. When cells were re- 
moved from the substrate by treatment with EDTA, the total 
binding of  labeled TN-C to the residual ECM and plastic was 
less than 15% of that to the intact cell layer. This implies that 
most of  the binding is to the cells. To determine what fraction 
of the TN-C might be internalized we treated the cells with 
trypsin after incubation with lz~I-TN-C. About 20%  of the 
total counts remained with the cell layer after trypsin treat- 
ment.  Thus the 50-60%  non-specific binding appears  to 
comprise: 15% to the ECM; 20% internalized by cells; and 
the remaining 15-25 % may be binding to trypsin accessible 
sites on the cell surface. 
Binding of soluble TN-C was also demonstrated to cells 
in suspension (Fig. 2 B).  Labeled tenascin bound to sus- 
pended glioma and endothelial cells similar to cells attached 
on substrate, but suspended fibroblasts showed much lower 
specific binding. Thus, the presence of receptors for TN-C 
on the surface of endothelial and gliorna cells, but not fibro- 
blasts, is indicated by both assays. 
To map the cell binding site(s) on TN-C, we tested the ac- 
tivity of recombinant expression proteins to compete with 
binding of native 12SI-TN-C. The strongest competitor was 
the alternatively spliced segment, TNfnA-D (Fig. 3).  The 
maximal competition by TNfnA-D was almost the same as 
that of native TN-C, but required a higher concentration on 
molar basis. Specifically, maximum inhibition was observed 
at  1 #g/ml for both native TN-C (Fig. 2 A, 4 nM in large 
subunit, based on the 240-kD peptide mass), and TNfnA-D 
(Fig. 3, A and B,  14 nM in the 70-kD expression protein). 
Half maximal inhibition by TNfnA-D was seen at the lowest 
concentration tested, 0.1 #g/nil or 1.5 nM, which is close to 
the 2-nM KD determined by Schatchard analysis (Fig. 5). 
This result indicates that both glioma and endothelial cells 
have  receptors  interacting  with  the  TNfnA-D  segment. 
Monomeric TN-C  produced by reduction and alkylation 
also competed well with radiolabeled hexameric TN-C (not 
shown). The TNfn3 domain, which has an RGD sequence, 
showed competition with TN-C in both cells but was less 
effective than TNfnA-D. TNfn6-8 and TNfbg showed mini- 
real competition even at 200-fold molar excess. 
As an alternative approach to test the importance of the 
TNfnA-D in binding to cells, we tested the two major splice 
variants of human TN-C, produced in transfected BHK cells 
(4). HxB.L is the large splice variant, and HxB.S is the small 
variant, missing the TNfnA-D segment. Both forms are as- 
sembled into apparently normal hexabrachions and secreted 
into the medium (4).  HxB.L showed specific binding to 
substrate-attached endothelial cells that was essentially iden- 
tical to TN-C (not shown). This result was expected because 
the human TN-C prepared from U-251MG glioma cells is 
,~90% the large splice variant. HxB.S showed a significantly 
lower total binding and no competition by 0.5-5.0 #g/ml cold 
HxB.S. A higher concentration of HxB.S (10 #g/mi) inhib- 
ited binding of radiolabeled HxB.S  ,~20%,  suggesting a 
small  amount of specific binding.  This  experiment  con- 
firms that the specific binding of TN-C to endothelial cells 
is mediated primarily by the alternatively spliced segment, 
TNfnA-D. 
Because TNfn3 showed substantial inhibition of  binding of 
native TN-C (Fig. 3), we tested its binding directly to cells. 
TNfn3 showed no significant binding to cells attached to 
substrate, but did bind to endothelial cells in suspension. 
This binding was inhibited by TNfnl-5 and by the peptide 
GRGDSP,  but not by GRGESP nor by TNfnA-D (data not 
shown). A combination of TNfn3 plus TNfnA-D competed 
more effectively than either protein alone for binding of na- 
tive TN-C  to cells, consistent with the hypothesis that these 
two domains bind to separate receptors. These experiments 
are all consistent with the previous conclusion that the w¢/33 
integrin on endothelial cells is a receptor for TNfn3 (36, 58). 
We therefore focused our efforts on the binding of TNfnA-D, 
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Figure 3.  Competition by re- 
combinant TN-C segments for 
t25I-TN-C binding to cells at- 
tached to the substrate. This 
experiment was similar to that 
in  Fig.  2  A,  but  competi- 
tors  were TNfnA-D, TNfn3, 
TNfn6-8,  and  TNfbg. They 
were added in varying  amounts 
with 125I-TN-C to cells (2  x 
105 cells per well) cultured on 
a substrate. The total binding 
of ~25I-TN-C in the absence of 
competitors is referred to as 
100%. The concentration for 
half  maximal competition was 
,~1.5 nM for TNfnA-D and 30 
nM  for  TNfn3. Each  data 
point is the mean of six mea- 
surements  from  three  inde- 
pendent experiments. 
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TN-C segments and ECM proteins. Competitors (10 ~tg/ml each) 
were added with mSI-TNfnA-D  (200 ng/ml) to cells cultured on a 
substrate. Binding of TNfnA-D in the absence of competitors is in- 
dicated as 0% competition. Each data point is the mean of six mea- 
surements from three independent experiments. Error bars indicate 
the standard error of the mean in Figs. 4, 5, and 9. 
which appears to be the most important domain for binding 
TN-C to cells,  and which involves a  previously unknown 
receptor. 
Cell Binding of  Labeled TNfnA-D 
To determine if both TNfnA-D and TNfn3 domains bind to 
the same receptor, we examined the competition between ra- 
diolabeled TNfnA-D and other domains and ECM proteins 
(Fig. 4).  Unlabeled TNfnA-D and native TN-C both com- 
peted well with ~25I-TNfnA-D for binding to both cells, but 
TNfn3,  TNfnl-5,  and  TNfbg could  not  displace  ~25I-TN- 
fnA-D at a 200-fold molar excess. In addition, fibronectin 
and laminin, major constituents of the ECM, did not com- 
pete for the binding of TNfnA-D. Thus, TNfnA-D appears 
to interact with a receptor on the cell surface that does not 
interact with other domains of TN-C. 
To characterize the receptor for TNfnA-D, we performed 
a saturation binding assay (Fig. 5). An apparent dissociation 
constant (KD) and numbers of binding sites for TNfnA-D 
were  calculated  from the  Scatchard  plot.  The  saturation 
binding data from GM7373 cells were fit well by a straight 
line determined with a  linear regression program.  This is 
consistent with a  single class of high affinity binding site. 
The apparent KD for TNfnA-D binding was 2  nM and the 
density of receptors was 3  ×  105 sites per cell. 
Identification of the Cell Surface Receptor 
The identification of the receptor was pursued by three tech- 
niques: (a) blot binding of cell extracts; (b) affinity column 
purification of labeled cell surface receptor from tissue cul- 
tures;  (c) bulk purification from bovine lung. 
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Figure 5. Saturation binding and derived Scatchard analysis (inset) 
for the binding of '25I-TNfnA-D to substrate-attached endothelial 
cells. Specific  binding represents the difference  between the binding 
in the absence and presence of a 100-fold excess of unlabeled li- 
gand. The Scatchard plot of the specific binding data are shown 
with the ratio bound/free and the amount of bound ligand as ng 
per 5  x  105 cells. The regression coefficient was ~/ =  0.94. Data 
points are the mean of six measurements. 
In the blot binding assay, TN-C selectively bound to three 
different polypeptides in octylglucoside extracts of cultured 
cells: 130, 48, and 35 kD (Fig. 6). Two or three minor bands 
between 48 and 130 kD were sometimes detected on blots. 
TNfnA-D bound to two of these three polypeptides, 48 and 
35 kD. TNfn3 did not bind to any proteins on the blot. Bind- 
ing of 12~I-TNfnA-D to the 35-kD band was blocked by add- 
ing unlabeled TNfnA-D but binding to the 48- and 130-kD 
was not inhibited (these two bands are weaker in Fig. 6 B 
than in 6 A, and are the same intensity with and without ex- 
cess TNfnA-D). The same three polypeptides were labeled 
in detergent extracts of both endothelial cells and glioma 
cells. 
We next used affinity chromatography to isolate the TN-C 
receptor(s). From endothelial cell extract, three major poly- 
peptides (140,  125, and 110 kD) were eluted with GRGDSP 
peptide  from the  TN-C  affinity column.  These proteins, 
which  are probably subunits  of integrins,  were absent in 
fractions eluted from TNfnA-D column.  A  major doublet 
band around 35 kD and a minor population of high molecu- 
lar weight proteins were eluted in the 4  M  urea fractions 
from both the TN-C and TNfrtA-D affinity columns (Fig. 7 
A). In other experiments, the same 35-kD doublet was eluted 
from both affinity columns with 0.5 M NaCI. In the 0.5 M 
NaC1 eluted fractions, high molecular weight proteins were 
not found in the autoradiogram. This 35-kD protein was also 
found in chromatography of glioma cell extracts (Fig. 7 B). 
Affinity columns of TNfn3, FN, and BSA did not bind the 
35-kD protein. In some experiments, the 35-kD protein was 
further purified by gel filtration on Superose-12 column in 
the presence of Triton X-100. The 35-kD protein was eluted 
in the late fractions from Superose-12 column. We referred 
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teins of  endothelial cells. (A) Proteins were extracted from cultured 
cells with 100 mM octylglucoside,  run on SDS-PAGE (10% gel), 
and transferred to a PVDF membrane. Remaining binding sites on 
the membrane were blocked with 5 % dry milk, and then incubated 
with  300  ng of I~I-TN-C  (106 cpm),  12SI-TNfnA-D (0.5  x  106 
cpm), or ~I-TNfn3 (0.5  ×  106 cpm) in I0 ml of D-TBS contain- 
ing 5 % heat-denatured BSA. After incubation for 2 h at room tem- 
perature,  the membrane was washed with D-TBS for 20 rain with 
four changes and dried  for autoradiography.  Arrows indicate la- 
beled bands of 130, 48, and 35 kD. (B) Another  blot binding of 
~'I-TNfnA-D to proteins of endothelial cells in the absence (a) or 
in the presence (b) of unlabeled TNfnA-D (20/~g/ml). Arrow indi- 
cates the 35-kD band. 
to this putative receptor as the 35-kD tenascin-binding pro- 
tein (TBP-35). 
Interestingly, two polypeptides (130 and 48 kD) identified 
in the ligand-blot (Fig. 6) were not major components in the 
autoradiogram from the affinity column. However, these two 
polypeptides were found  in  silver-stained gels  of cell  ex- 
tracts, so they may be relatively abundant cytoskeletal pro- 
teins. 
Because tissue culture cells are expensive to produce in 
large quantity,  we tried to purify the TBP-35 protein from 
bovine lung,  which should be a  rich source of endothelial 
cells. Lung membrane extract was made by differential cen- 
trifugation,  the  membrane  fraction  was  solubilized  with 
0.2% Triton X-100, and the extract was loaded onto affinity 
columns. A TBP-35 protein, identified by Coomassie blue- 
stained SDS-PAGE,  was eluted from both TN-C and TN- 
fnA-D affinity columns with 0.5 M NaC1 or urea (Fig. 8 A). 
We tested the specificity of this protein by the blot binding 
assay.  TNfnA-D  bound  to  several proteins  including  the 
TBP-35 protein in the lung membrane extract (Fig. 8 B). The 
binding of m25I-TNfnA-D to those proteins was blocked by 
the  presence  of excess  soluble  TNfnA-D.  TNfnA-D  also 
bound to the partially purified TBP-35. 
Annexin 1I: the Receptor for Tenascin 
To determine whether TBP-35 was a new protein or a protein 
Figure 7,  Endothelial  (A)  and  glioma (B)  cell  extracts  affinity  puri- 
fied  on native  TN-C and TNfnA-D  affifiity  columns.  Glioma and 
endothelial  ceils  (I0  s  cells)  were surface  labeled  with 12sI  by using 
lactoperoxidase  and extracted with  100 mM octylglucoside.  The 
extract (3 ml, lane T) was loaded onto the affinity column (2 ml). 
Fractions  (1 ml each) were collected and  100 pl of each fraction 
was analyzed by SDS-PAGE (8%) under reducing condition.  (A) 
Where indicated by arrows, 1 mg/ml of the synthetic peptide GRG- 
DSP and 4 M urea was added to the elution buffer. (B) Lanes 1 and 
2, fractions eluted with 1 mg/ml of GRGDSP peptide; lanes 3 and 
4, fractions eluted with 4 M urea. Molecular weight markers (lane 
M) in A were phosphorylase  B, 97.4 kD; bovine serum albumin, 
66.2 kD; ovalbumin, 43 kD; carbonic anhydrase, 31 kD; soybean 
trypsin inhibitor, 21.5 kD. Molecular weight markers in B were my- 
osin, 200 kD; b-galactosidase,  116 kD; phosphorylase b, 97.4 kD; 
bovine serum albumin,  66.2 kD; ovalbumin, 45 kD. 
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staining of SDS-PAGE of (a) 
lung  membrane  extract,  (b) 
protein eluted from the TN-C 
affinity  column  by  0.5  M 
NaC1, and (c) further purified 
by gel filtration on a Superose 
6 column. Lane m shows mo- 
lecular weight markers,  as in 
Fig. 7. (B) Blot binding assay 
with  I~I-TNfnA-D (5  x  lO  s 
cpm):  a  and  c,  lung  mem- 
brane extract; b and d, 35-kD 
protein  after purification  on 
Superose-6. For c and d, the 
blot binding assay was done in 
the presence of 20 #g/ml un- 
labeled TNfnA-D. The arrow 
head  indicates  the  35-kD  re- 
ceptor. 
already known, the 35-kD band was separated by SDS-PAGE 
and sent to Harvard Microchemistry Facility for amino acid 
sequence analysis. Three internal sequences were obtained 
from tryptic peptides of TBP-35. The sequences were run on 
a database and two amino acid sequences, SLYYYIQQDTK 
and EVDMLK,  were identical to sequences in bovine an- 
nexin II. Annexin II is a 35-kD protein, thus matching the 
size  of our  TBP-35  band.  Another  sequence,  FGDGYN- 
GYGG, was identical to the sequence of small ribonuclear 
protein, which is also a 35-kD protein. This sequence is ap- 
parently from a contaminating nuclear protein in our TBP-35 
preparation. 
To  test  whether  annexin  II could  indeed  function  as  a 
receptor for TNfnA-D, we obtained some purified annexin 
II,  and  a  polyclonal  antibody  against  it,  from  Dr.  Carl 
Creutz,  University  of  Virginia.  The  purified  annexin  II 
bound to the TNfnA-D affinity column and was eluted with 
0.5 M NaC1. In Western blots the antibody to annexin II and 
our anti-TBP-35 both stained purified armexin II and the 35- 
kD  band  in  membrane extracts  (not  shown).  Finally,  the 
affinity purified polyclonal antibody against purified annexin 
II was tested for its ability to block binding of ~25I-TNfnA-D 
to endothelial cells. As seen in Fig. 9, this antibody blocked 
binding in a concentration dependent manner, and the maxi- 
mum inhibition by the antibody was approximately the same 
as by native TN-C. Our anti-TBP-35 antibody also blocked 
this binding (not shown). 
The binding of purified annexin II to TN-C was further 
tested in a  solid phase binding assay. TN-C was coated on 
plastic,  and  incubated with  ~25I-labeled annexin II plus in- 
creasing amounts of unlabeled annexin II (Fig.  10).  Labeled 
annexin  II was  displaced  as  the  unlabeled  annexin  II in- 
creased from 0.15  to 0.6  #g/ml (4-17 riM).  The affinity of 
purified annexin II for TN-C in this assay is thus comparable 
to  the  2  nM  Kr,  determined  for binding  of TN-C to  en- 
dothelial cells. 
Is Annexin  H  on the Cell Surface? 
If annexin II is the receptor for TN-C, it must be exposed 
on the external cell surface. This implication was at first sur- 
prising since annexin II is well characterized as a cytoplas- 
mic protein, and it has no hydrophobic signal sequence for 
secretion.  It is unlikely that annexin II on the cell surface 
could have come from the fetal calf serum; annexin II has 
never been reported in serum, and our own Western blots of 
serum failed to detect it (not shown).  Thus, the annexin II 
exposed on the cell surface was apparently synthesized by the 
endothelial cells and  somehow translocated to the outside 
Figure 9.  Inhibition of t25I-TNfnA-D  binding to endothelial  cells 
by afffinity-purified  annexin I1 antibody. Endothelial cells (5  x  los 
cells  per tube)  were harvested  with  3 mM EDTA, washed with 
DMEM/Hepes two times, and incubated with t:ZI-TNfnA-D  in the 
absence  or presence  of various competitors  and affinity purified 
anti-annexin II antibody (1, 5, and 10 #g per ml) for 1 h at 37°C. 
After incubation,  cells were loaded onto a discontinuous  sucrose 
gradient and pelleted as described in Materials and Methods. Each 
data point is the mean of three measurements.  The first bar shows 
total binding of TNfnA-D in the absence of inhibitor. Inhibitors are 
indicated above the bars and the concentration of inhibitors in/zg/ 
ml is in parenthesis. 
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Figure 10. Binding of annexin n to tenascin. Tenascin  (10 #g per 
well) was coated on a plastic 96 well plate and the remaining bind- 
ing sites were blocked with 5 % dry milk.  nSI-aunexin II (120 ng 
per well,  105 cpm),  100/zg/ml  BSA, and increasing amounts of 
unlabeled annexin II were added to each well and incubated for 2 h 
at room temperature. The plate was washed with D-TBS and ex- 
tracted with 2 % SDS for determination of annexin binding. 
surface. To examine whether annexin II was actually exposed 
on the surface of  the endothelial cells, we used flow cytomet- 
ric analysis. Living cells were stained with antibodies and 
subsequently fixed and subjected to flow cytometric analy- 
sis.  Fig.  11 demonstrates that cells stained with preimmune 
or with spectrin antibodies gave minimal fluorescence, while 
cells stained with antibodies against annexin II, or our own 
antibody against TBP-35, gave prominent staining. 
These  results  were  confirmed  by  immunofluorescence 
staining  (not shown).  Affinity purified spectrin antibodies 
stained ceils only when they were permeabilized. In con- 
trast, annexin II antibodies gave prominent staining of un- 
permeabilized cells, as well as of permeabilized cells. These 
results confirm that there is a substantial amount of annexin 
II exposed on the cell surface. 
Discussion 
The biological significance of the alternatively spliced re- 
gion of TN-C has been emphasized by several reports show- 
ing that the large TN-C splice variant is expressed in the on- 
set  of important  cellular processes  that  need  active cell 
migration or tissue remodeling. Oyama et al.  (53) showed 
that transformed fibroblasts and fetal lung tissue expressed 
more TN-C mRNA with the A-D domains than normal cells 
and adult tissue. The expression of the largest chicken TN-C 
variant is correlated with cell migration into the developing 
cornea (38). The large TN-C variant was absent in normal 
adult mouse skin, but reappeared in healing skin and again 
disappeared after wound healing (17).  Thus, this segment 
may have a stimulatory effect on cell migration and tissue 
remodeling, possibly through a receptor-mediated cell sig- 
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Figure 11. Flow cytometric analysis of expression of the annexin II 
on endothelial cell surface. One million cells were labeled with four 
different antibodies.  Preimmune  antibody  (1:200 dilution)  and 
afffinity-purified  spectrin antibody (5/zg/ml) were used as a negative 
control. TBP-35 and annexin II antiserum were also added at a final 
dilution 1:200. 
naling mechanism. Murphy-Ullrich et al.  (51) showed that 
soluble TN-C, or the segment TNfnA-D, induced the loss of 
focal adhesions in well-spread endothelial cells, and Julian 
et al.  (37)  found that TNf-nA-D  inhibited the adhesion of 
uterine epithelial cells to matrigel. The receptor that we have 
identified here may be the one that initiates these responses. 
In this study, we have found a protein or pair of proteins 
with molecular weight around 35 kD as a candidate receptor 
for the alternatively spliced region of  tenascin. Purified TBP- 
35 from cells or lung was usually seen as a doublet band in 
SDS-PAGE. In the blot assay,  labeled ligand usually bound 
to only one or two of the ,,o35-kD bands. In the most freshly 
prepared membrane extracts, we frequently see a single band 
of the 35-kD protein, whereas two lower molecular weight 
bands appear at later times. This implies a proteolytic cleav- 
age, which is consistent with the identification of the recep- 
tor as annexin II. Annexin II has two protease cleavage sites 
near the NH2 terminus,  which are likely to produce three 
closely spaced bands on SDS-PAGE. 
We identified the 35-kD receptor to be annexin II, which 
is  a  member of the annexin family of calcium-dependent 
phospholipid-binding  proteins  (11). Although  the  precise 
functions of these proteins are not known, they have been 
reported to play roles in the regulation of membrane fusion 
in exocytosis (2), control of the activity of phospholipase 
A2 (42),  and signal transduction by serving as a  substrate 
for the tyrosine kinase encoded by the src oncogene (31). An- 
nexins  lack  a  hydrophobic signal  sequence and  are  well 
characterized as intracellular proteins. Since the receptor for 
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protein,  we  undertook the  extensive  analysis  reported  in 
Figs. 9-11 to demonstrate that annexin II was present on the 
external cell surface and that it was indeed the receptor for 
TNfnA-D. 
In addition to our own analysis, there are several recent 
studies demonstrating that annexins can be secreted or ex- 
posed on the external cell surface. Christmas et al. (16) found 
that human seminal plasma contained a high concentration 
of annexin I secreted from the prostate gland. The annexin 
I present in seminal plasma does not originate from cell lysis 
because the concentration of annexin I in plasma is much 
higher  than in the  prostate  gland  itself.  Annexin  V  was 
reported to be secreted from chick embryo fibroblasts with- 
out cell  lysis  (40).  There are also previous reports of an- 
nexins binding to extracellular matrix molecules. Annexin V 
binds to type II and X collagen and appears to be localized 
in the extracellular matrix of calcifying cartilage (39). Het- 
erogeneous expression of annexins (I-VI) on the external cell 
surface of human and rodent tumor cells has been reported 
(62).  The mechanism of secretion of annexins is still com- 
pletely unknown, but the fact that they are exported from the 
cytoplasm, and that they bind to the cell surface and to ex- 
tracellular matrix molecules, is becoming well established. 
The recent study of Tressler et al. (59) is particularly rele- 
vant to our present results. Annexin 1I was found to be prom- 
inently expressed on the external surface of a lymphoma cell 
line, and it mediated adhesion of these lymphoma ceils to he- 
patic sinusoid endothelial cells. The role of endothelial ceils 
appears to be different in their study and ours. In our study 
the membrane-bound and exposed  armexin II  was  on en- 
dothelial  ceils,  and  it  bound to  the  extracellular  protein 
TN-C.  In their study the armexin II was on the lymphoma 
cells, and it bound to an unknown receptor on the endothelial 
cells. The binding to this endothelial cell receptor is similar 
to the binding TN-C in that it is reversed by 0.5 M  NaC1. 
Tressler et al. did not analyze their endothelial cells for ex- 
posed annexin II, but another recent study reported annexin 
II on human umbilical vein endothelial ceils (61). In this con- 
text the annexin II served as a receptor for cytomegalovirus. 
The affinity of annexin II for cytomegalovirus was 57 nM, 
about ten times weaker than the affinity for TNfnA-D. 
The concentration of TN-C has been estimated at about 1 
mg/ml  in tumor matrix  and in the most concentrated ex- 
tracellular clefts of brain (45), giving a concentration of 2.4 
×  10  -~  M  in  the  240-kD  subunits.  This  is  1,000  times 
higher than the KD for dissociation from annexin II, mean- 
ing that all extracellular annexin II should have bound TN-C 
in these tissues. 
What is the possible physiological significance of TN-C 
binding to cell surface annexin II? One possibility is that an- 
nexin II associates  directly with and activates cell  surface 
receptors on the same cell, this association being modulated 
by the binding of the TNfnA-D ligand. A  most interesting 
possibility is that annexin II may be directly involved in sig- 
nal transduction. The crystal structure of annexin V  shows 
a central channel that has been implicated as a possible cal- 
cium channel (35). Armexin V demonstrates calcium chan- 
nel activity when absorbed onto lipid membranes,  and the 
selectivity of the channel is altered by a mutation in the puta- 
tive channel (7). Annexin II has a similar structure (12) and 
may have similar channel activity. The mechanisms by which 
annexins are bound on the external surface of a membrane, 
and how they might allow passage of ions through the mem- 
branes,  are completely unknown, but the possible channel 
activity of these proteins could allow them to operate di- 
rectly  in signal transduction.  It will be interesting to test 
whether binding of TNfnA-D,  the highest affinity protein 
ligand for annexin II, can modulate its channel activity. 
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